Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

📅 09/09/2026 10:15 📰 biospace 👁️ 0 lectures 🌍 États-Unis 📂 Actualités